To investigate the clinical value of tumor marker combined with cytokeratin 18 and 19 in the diagnosis of malignant tumors.

264 patients with malignant tumor were selected as the observation group.During the same period, 136 patients with benign tumor were selected as the control group.The tumor markers, cytokeratin 18 (CK18) and cytokeratin 19 (CK19) levels were compared between the two groups, and the positive detection rate of tumor markers combined with CK18 and CK19 were analyzed.

The serum CK18 and CK19 levels of the observation group were (25.48±75.14) U/L, (18.67±64.85)U/L, respectively, which were significantly higher than those of the control group[(0.56±1.52)U/L, (0.76±0.43)U/L], the differences were statistically significant (t=17.38, 15.75, all P<0.05). The serum levels of CEA, CA125, CA50, CA19-9 and TSGF of the observation group were (21.24±30.16) μg/L, (69.85±112.75) mU/L, (47.32±121.81)mU/L, (41.87±20.65) mU/L, (91.64±43.84) mU/L, respectively, which were significantly higher than those of the control group [(1.27±0.85) ng/mL, (15.82±3.87) mU/L, (12.85±31.65) mU/L, (6.89±4.85) mU/L, (38.35±8.01) mU/L], the differences were statistically significant (t= 15.73, 16.89, 14.86, 17.79, 16.73, all P<0.05). The positive detection rates of CK18 and CK19 for gastric cancer (66.67%) and lung cancer (77.14%) were significantly higher than tumor markers, and the differences were statistically significant (χ²=5.67, 6.78, all P<0.05). The positive detection rate of tumor markers combined with CK18 and CK19 for malignant tumors (75.00%) was significantly higher than CK18 and CK19 joint detection (65.91%), tumor markers (46.97%), the differences were statistically significant (χ²=6.78, 7.12, all P<0.05).

Tumor markers combined with CK18 and CK19 detection is helpful to improve the detection rate of malignant tumors and provide effective basis for following treatment.

Tumor markers, biological; Keratins; Neoplasms; Diagnosis